Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint therapy in liver cancer
Feng Xu, Tianqiang Jin, Yuwen Zhu, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 340

Showing 1-25 of 340 citing articles:

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 290
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 276
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang, Gaochao Guo, Hui Guan, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 237
Immunotherapy for hepatocellular carcinoma
Zongyi Yin, Xiaowu Li
Cancer Letters (2019) Vol. 470, pp. 8-17
Closed Access | Times Cited: 217
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
Jianming Shen, Hui Shen, Lixin Ke, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 107
Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects
Basil Alawyia, Constantina Constantinou
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 7, pp. 711-724
Closed Access | Times Cited: 71
Nanoparticle drug delivery systems for synergistic delivery of tumor therapy
Daoyuan Chen, Xuecun Liu, Xiaoyan Lu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 55
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Xiaoting Luo, Xin He, Xingmei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 32
Role of the Gut–Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship
Naoko Ohtani, Norifumi Kawada
Hepatology Communications (2019) Vol. 3, Iss. 4, pp. 456-470
Open Access | Times Cited: 144
Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images
Yao Zhao, Yi Dong, Guoqing Wu, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 112
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed Onuma, Hongji Zhang, Hai Huang, et al.
Gene Expression (2020) Vol. 20, Iss. 1, pp. 53-65
Open Access | Times Cited: 78
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, et al.
Drug Resistance Updates (2020) Vol. 51, pp. 100702-100702
Open Access | Times Cited: 77
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico, Angelica Petrillo, Pasqualina Giordano, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 3025-3025
Open Access | Times Cited: 71
M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway
Jian Pu, Zuoming Xu, Jiahui Nian, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 69
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma
Juan Cai, Zhiqiang Chen, Yao Zhang, et al.
Molecular Therapy — Oncolytics (2022) Vol. 24, pp. 755-771
Open Access | Times Cited: 66
The Immunology of Hepatocellular Carcinoma
Gbemisola Lawal, Yao Xiao, Amir A. Rahnemai‐Azar, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1184-1184
Open Access | Times Cited: 63
The progress of immune checkpoint therapy in primary liver cancer
Yi-Min Zheng, Siwei Wang, Jia‐Bin Cai, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188638-188638
Closed Access | Times Cited: 63
T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy
Zhanyan Gao, Yang Feng, Jinhua Xu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma
Hongjun Xie, Muqi Shi, Yifei Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
Abdelrahman Abaza, Faten Sid Idris, Humna Anis Shaikh, et al.
Cureus (2023)
Open Access | Times Cited: 34
Curcumin in the treatment of liver cancer: From mechanisms of action to nanoformulations
Sulieman Ibraheem Shelash Al‐Hawary, Saade Abdalkareem Jasim, Mustafa M. Kadhim, et al.
Phytotherapy Research (2023) Vol. 37, Iss. 4, pp. 1624-1639
Closed Access | Times Cited: 33
POSTN+cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma
Hao Wang, Yuan Liang, Zheng Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008721-e008721
Open Access | Times Cited: 13
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 4, pp. 400-412
Open Access | Times Cited: 8
IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion
Lina Herhaus, Uxía Gestal Mato, Vinay V. Eapen, et al.
Cell (2024)
Open Access | Times Cited: 8
Recombinant CD80 fusion protein combined with discoidin domain receptor 1 inhibitor for cancer treatment
Songna Wang, Pinliang Hu, Xuyao Zhang, et al.
Applied Microbiology and Biotechnology (2025) Vol. 109, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top